# Phase I Combination w/ Epirubicin

> **NCT00322374** · PHASE1 · COMPLETED · sponsor: **R-Pharm** · enrollment: 42 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Ixabepilone
- **DRUG:** Epirubicin

## Key facts

- **NCT ID:** NCT00322374
- **Lead sponsor:** R-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2016-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00322374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00322374, "Phase I Combination w/ Epirubicin". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00322374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*